PMID- 29855363
OWN - NLM
STAT- MEDLINE
DCOM- 20180730
LR  - 20231112
IS  - 1472-6882 (Electronic)
IS  - 1472-6882 (Linking)
VI  - 18
IP  - 1
DP  - 2018 May 31
TI  - Herbal formula Xinshuitong capsule exerts its cardioprotective effects via 
      mitochondria in the hypoxia-reoxygenated human cardiomyocytes.
PG  - 170
LID - 10.1186/s12906-018-2235-4 [doi]
LID - 170
AB  - BACKGROUND: The collapse of mitochondrial membrane potential (DeltaPsim) resulted in 
      the cell apoptosis and heart failure. Xinshuitong Capsule (XST) could ameliorate 
      left ventricular ejection fraction (LVEF), New York Heart Association (NYHA) 
      classes and the quality of life in patients with chronic heart failure in our 
      clinical study, however, its cardioprotective mechanisms remain unclear. METHODS: 
      Primary human cardiomyocytes were subjected to hypoxia-reoxygenation and treated 
      with XST200, 400 and 600 mug/ml. The model group was free of XST and the control 
      group was cultured in normal conditions. Cell viability, DeltaPsim, the activity of 
      mitochondrial respiratory chain complexes, ATPase activity, reactive oxygen 
      species (ROS) and apoptosis cells were determined in all the groups. RESULTS: The 
      cell viability in the XST-treated groups was significantly higher than that in 
      the model group (P < 0.05). Coupled with the restoration of the DeltaPsim, the number 
      of polarized cells increased dose dependently in the XST-treated groups. XST also 
      restored the lost activities of mitochondrial respiratory chain complexes I-IV 
      induced by the oxidative stress. The total of mitochondrial ATPase activity was 
      significantly elevated at XST400 and 600 mug/ml compared to the model group 
      (P < 0.05). The levels of mitochondrial ROS and the number of apoptosis cells 
      declined in the XST-treated groups compared to those in the model group 
      (P < 0.05). CONCLUSIONS: XST, via restoration of DeltaPsim and the mitochondrial 
      respiratory chain complexes I-IV activities, and suppression of mitochondrial ROS 
      generation and the apoptosis cells, maintained the integrity of the mitochondrial 
      membrane to exert its cardioprotective effects in the hypoxia-reoxygenated human 
      cardiomyocytes.
FAU - Tan, Chunjiang
AU  - Tan C
AD  - Fujian Academy of Integrative Medicine, Fujian University of Traditional Chinese 
      Medicine, Fuzhou, Fujian, China. tchunj@126.com.
FAU - Zeng, Jianwei
AU  - Zeng J
AD  - Fujian Academy of Integrative Medicine, Fujian University of Traditional Chinese 
      Medicine, Fuzhou, Fujian, China.
FAU - Wu, Yanbin
AU  - Wu Y
AD  - Fujian Academy of Integrative Medicine, Fujian University of Traditional Chinese 
      Medicine, Fuzhou, Fujian, China.
FAU - Zhang, Jiahui
AU  - Zhang J
AD  - Fujian Academy of Integrative Medicine, Fujian University of Traditional Chinese 
      Medicine, Fuzhou, Fujian, China.
FAU - Chen, Wenlie
AU  - Chen W
AD  - Fujian Academy of Integrative Medicine, Fujian University of Traditional Chinese 
      Medicine, Fuzhou, Fujian, China.
LA  - eng
PT  - Journal Article
DEP - 20180531
PL  - England
TA  - BMC Complement Altern Med
JT  - BMC complementary and alternative medicine
JID - 101088661
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Drugs, Chinese Herbal)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Apoptosis/drug effects
MH  - Cardiotonic Agents/*pharmacology
MH  - Cell Hypoxia/*drug effects
MH  - Cell Survival/drug effects
MH  - Cells, Cultured
MH  - Drugs, Chinese Herbal/*pharmacology
MH  - Flow Cytometry
MH  - Humans
MH  - Membrane Potential, Mitochondrial/drug effects
MH  - Mitochondria/*drug effects
MH  - Myocytes, Cardiac/*drug effects
MH  - Oxygen/metabolism
PMC - PMC5984388
OTO - NOTNLM
OT  - Hypoxia-reoxygenated human cardiomyocytes
OT  - Mitochondrial potential
OT  - Xinshuitong capsule
COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: Not applicable. COMPETING INTERESTS: 
      The authors declare that they have no competing interests. PUBLISHER'S NOTE: 
      Springer Nature remains neutral with regard to jurisdictional claims in published 
      maps and institutional affiliations.
EDAT- 2018/06/02 06:00
MHDA- 2018/07/31 06:00
PMCR- 2018/05/31
CRDT- 2018/06/02 06:00
PHST- 2018/03/14 00:00 [received]
PHST- 2018/05/21 00:00 [accepted]
PHST- 2018/06/02 06:00 [entrez]
PHST- 2018/06/02 06:00 [pubmed]
PHST- 2018/07/31 06:00 [medline]
PHST- 2018/05/31 00:00 [pmc-release]
AID - 10.1186/s12906-018-2235-4 [pii]
AID - 2235 [pii]
AID - 10.1186/s12906-018-2235-4 [doi]
PST - epublish
SO  - BMC Complement Altern Med. 2018 May 31;18(1):170. doi: 10.1186/s12906-018-2235-4.